360Dx

Natera's Q1 2017 Revenues Drop 24 Percent

May 09, 2017

NEW YORK (GenomeWeb) – Natera reported after the market on Tuesday that its first quarter 2017 revenues declined 24 percent over the first quarter 2016.

The San Carlos, California-based molecular diagnostics firm recognized $46.9 million in Q1 revenues, down from $61.9 million in Q1 2016. It beat analysts' average estimate of $42.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Natera's Q1 2017 Revenues Drop 24 Percent

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Illumina to Acquire Grail for $8B in Cash and Stock

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships